Verona Pharma (VRNA) Stock Forecast, Price Target & Predictions
VRNA Stock Forecast
Verona Pharma stock forecast is as follows: an average price target of $33.00 (represents a -13.50% downside from VRNA’s last price of $38.15) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
VRNA Price Target
The average price target for Verona Pharma (VRNA) is $33.00 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $38.00 to $26.00. This represents a potential -13.50% downside from VRNA's last price of $38.15.
VRNA Analyst Ratings
According to 8 Wall Street analysts, Verona Pharma's rating consensus is 'Buy'. The analyst rating breakdown for VRNA stock is 0 'Strong Buy' (0.00%), 8 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Verona Pharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 22, 2024 | Edward Nash | Canaccord Genuity | $37.00 | $22.95 | 61.22% | -3.01% |
| Jun 27, 2024 | Raghuram Selvaraju | H.C. Wainwright | $36.00 | $14.69 | 145.06% | -5.64% |
| May 28, 2024 | Andrew Tsai | Jefferies | $38.00 | $12.50 | 204.00% | -0.39% |
| Apr 16, 2024 | Yasmeen Rahimi | Piper Sandler | $36.00 | $15.80 | 127.85% | -5.64% |
| Dec 21, 2022 | - | H.C. Wainwright | $32.00 | $18.59 | 72.14% | -16.12% |
| Dec 20, 2022 | Andreas Argyrides | Wedbush | $30.00 | $18.05 | 66.20% | -21.36% |
| Dec 20, 2022 | - | Truist Financial | $28.00 | $18.13 | 54.48% | -26.61% |
| Dec 20, 2022 | - | BTIG | $26.00 | $18.14 | 43.29% | -31.85% |
| Aug 30, 2022 | Edward Nash Nash | Canaccord Genuity | $27.00 | $10.25 | 163.41% | -29.23% |
| Aug 30, 2022 | Raghuram Selvaraju Selvaraju | H.C. Wainwright | $30.00 | $9.90 | 203.03% | -21.36% |
The latest Verona Pharma stock forecast, released on Jul 22, 2024 by Edward Nash from Canaccord Genuity, set a price target of $37.00, which represents a 61.22% increase from the stock price at the time of the forecast ($22.95), and a -3.01% decrease from VRNA last price ($38.15).
Verona Pharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 4 |
| Avg Price Target | - | - | $36.75 |
| Last Closing Price | $38.15 | $38.15 | $38.15 |
| Upside/Downside | -100.00% | -100.00% | -3.67% |
In the current month, the average price target of Verona Pharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Verona Pharma's last price of $38.15. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 03, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Oct 03, 2024 | Wells Fargo | - | Overweight | Initialise |
| Sep 12, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 14, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 22, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Jun 27, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 27, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 16, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Dec 20, 2022 | BTIG | Buy | Buy | Hold |
Verona Pharma's last stock rating was published by Piper Sandler on Oct 03, 2024. The company gave VRNA a "Overweight" rating, the same as its previous rate.
Verona Pharma Financial Forecast
Verona Pharma Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $458.00K | - | $40.00M |
| Avg Forecast | $30.95M | $23.36M | $17.19M | $9.79M | $4.84M | $1.51M | $263.34K | $4.08M | $4.52M | $4.63M |
| High Forecast | $30.95M | $23.36M | $17.19M | $9.79M | $4.84M | $2.29M | $263.34K | $4.08M | $4.52M | $4.63M |
| Low Forecast | $30.95M | $23.36M | $17.19M | $9.79M | $4.84M | $491.46K | $263.34K | $4.08M | $4.52M | $4.63M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 3 | 3 | 4 |
| Surprise % | - | - | - | - | - | - | - | 0.11% | - | 8.65% |
Verona Pharma's average Quarter revenue forecast for Jun 24 based on 4 analysts is $263.34K, with a low forecast of $263.34K, and a high forecast of $263.34K. VRNA's average Quarter revenue forecast represents a -42.50% decrease compared to the company's last Quarter revenue of $458.00K (Dec 22).
Verona Pharma EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 3 | 3 | 4 |
| EBITDA | - | - | - | - | - | - | - | $-12.24M | $-12.06M | $11.43M |
| Avg Forecast | $-6.19M | $-4.67M | $-3.44M | $-1.96M | $-968.48K | $-302.74K | $-52.67K | $-815.19K | $-903.90K | $-925.22K |
| High Forecast | $-6.19M | $-4.67M | $-3.44M | $-1.96M | $-968.48K | $-98.29K | $-52.67K | $-815.19K | $-903.90K | $-925.22K |
| Low Forecast | $-6.19M | $-4.67M | $-3.44M | $-1.96M | $-968.48K | $-458.70K | $-52.67K | $-815.19K | $-903.90K | $-925.22K |
| Surprise % | - | - | - | - | - | - | - | 15.01% | 13.35% | -12.35% |
3 analysts predict VRNA's average Quarter EBITDA for Sep 22 to be $-903.90K, with a high of $-903.90K and a low of $-903.90K. This is -107.91% lower than Verona Pharma's previous annual EBITDA (Sep 21) of $11.43M.
Verona Pharma Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 3 | 3 | 4 |
| Net Income | - | - | - | - | - | - | - | $-10.45M | $-15.65M | $11.05M |
| Avg Forecast | $-2.55M | $-3.19M | $-3.03M | $-3.35M | $-4.60M | $-4.12M | $-2.88M | $372.21K | $-878.88K | $-11.53M |
| High Forecast | $-2.55M | $-3.19M | $-3.03M | $-3.35M | $-4.60M | $-3.66M | $-2.88M | $372.21K | $-878.88K | $-11.53M |
| Low Forecast | $-2.55M | $-3.19M | $-3.03M | $-3.35M | $-4.60M | $-5.12M | $-2.88M | $372.21K | $-878.88K | $-11.53M |
| Surprise % | - | - | - | - | - | - | - | -28.08% | 17.80% | -0.96% |
Verona Pharma's average Quarter net income forecast for Sep 22 is $-878.88K, with a range of $-878.88K to $-878.88K. VRNA's average Quarter net income forecast represents a -107.95% decrease compared to the company's last Quarter net income of $11.05M (Sep 21).
Verona Pharma SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 3 | 3 | 4 |
| SG&A | - | - | - | - | - | - | - | $8.32M | $5.29M | $10.88M |
| Avg Forecast | $24.06B | $18.16B | $13.36B | $7.61B | $3.76B | $1.18B | $204.70M | $3.17B | $3.51B | $3.60B |
| High Forecast | $24.06B | $18.16B | $13.36B | $7.61B | $3.76B | $1.78B | $204.70M | $3.17B | $3.51B | $3.60B |
| Low Forecast | $24.06B | $18.16B | $13.36B | $7.61B | $3.76B | $382.04M | $204.70M | $3.17B | $3.51B | $3.60B |
| Surprise % | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.00% |
Verona Pharma's average Quarter SG&A projection for Jun 24 is $204.70M, based on 4 Wall Street analysts, with a range of $204.70M to $204.70M. The forecast indicates a 2359.49% rise compared to VRNA last annual SG&A of $8.32M (Dec 22).
Verona Pharma EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 3 | 3 | 4 |
| EPS | - | - | - | - | - | - | - | $-0.18 | $-0.23 | $0.16 |
| Avg Forecast | $-0.03 | $-0.04 | $-0.04 | $-0.04 | $-0.06 | $-0.05 | $-0.04 | - | $-0.01 | $-0.14 |
| High Forecast | $-0.03 | $-0.04 | $-0.04 | $-0.04 | $-0.06 | $-0.05 | $-0.04 | - | $-0.01 | $-0.14 |
| Low Forecast | $-0.03 | $-0.04 | $-0.04 | $-0.04 | $-0.06 | $-0.06 | $-0.04 | - | $-0.01 | $-0.14 |
| Surprise % | - | - | - | - | - | - | - | -39.18% | 21.20% | -1.12% |
According to 3 Wall Street analysts, Verona Pharma's projected average Quarter EPS for Sep 22 is $-0.01, with a low estimate of $-0.01 and a high estimate of $-0.01. This represents a -106.78% decrease compared to VRNA previous annual EPS of $0.16 (Sep 21).
Verona Pharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.15 | $33.86 | 1474.88% | Buy |
| XFOR | X4 Pharmaceuticals | $0.53 | $3.67 | 592.45% | Buy |
| INZY | Inozyme Pharma | $4.42 | $14.67 | 231.90% | Buy |
| APLS | Apellis Pharmaceuticals | $28.56 | $76.13 | 166.56% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.81 | $38.80 | 161.99% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.95 | $7.00 | 137.29% | Buy |
| TERN | Terns Pharmaceuticals | $7.10 | $14.25 | 100.70% | Buy |
| SNDX | Syndax Pharmaceuticals | $18.94 | $36.11 | 90.65% | Buy |
| MLTX | MoonLake Immunotherapeutics | $46.40 | $79.33 | 70.97% | Buy |
| MREO | Mereo BioPharma Group | $4.01 | $6.75 | 68.33% | Buy |
| IDYA | IDEAYA Biosciences | $30.00 | $48.36 | 61.20% | Buy |
| VKTX | Viking Therapeutics | $63.14 | $100.50 | 59.17% | Buy |
| AKRO | Akero Therapeutics | $32.05 | $46.00 | 43.53% | Buy |
| PTGX | Protagonist Therapeutics | $46.76 | $50.00 | 6.93% | Buy |
| MDGL | Madrigal Pharmaceuticals | $331.32 | $315.75 | -4.70% | Buy |
| AMLX | Amylyx Pharmaceuticals | $5.70 | $5.33 | -6.49% | Buy |
| VRNA | Verona Pharma | $38.15 | $33.00 | -13.50% | Buy |
VRNA Forecast FAQ
Is Verona Pharma a good buy?
Yes, according to 8 Wall Street analysts, Verona Pharma (VRNA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 8 'Buy' recommendations, accounting for 100.00% of VRNA's total ratings.
What is VRNA's price target?
Verona Pharma (VRNA) average price target is $33 with a range of $26 to $38, implying a -13.50% from its last price of $38.15. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Verona Pharma stock go up soon?
According to Wall Street analysts' prediction for VRNA stock, the company can go down by -13.50% (from the last price of $38.15 to the average price target of $33), down by -0.39% based on the highest stock price target, and down by -31.85% based on the lowest stock price target.
Can Verona Pharma stock reach $60?
VRNA's average twelve months analyst stock price target of $33 does not support the claim that Verona Pharma can reach $60 in the near future.
What are Verona Pharma's analysts' financial forecasts?
Verona Pharma's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $6.62M (high $7.4M, low $5.6M), average EBITDA is $-1.324M (high $-1.119M, low $-1.48M), average net income is $-11.596M (high $-11.138M, low $-12.602M), average SG&A $5.15B (high $5.75B, low $4.35B), and average EPS is $-0.143 (high $-0.137, low $-0.156). VRNA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $81.29M (high $81.29M, low $81.29M), average EBITDA is $-16.258M (high $-16.258M, low $-16.258M), average net income is $-12.135M (high $-12.135M, low $-12.135M), average SG&A $63.19B (high $63.19B, low $63.19B), and average EPS is $-0.15 (high $-0.15, low $-0.15).
Did the VRNA's actual financial results beat the analysts' financial forecasts?
Based on Verona Pharma's last annual report (Dec 2022), the company's revenue was $458K, which missed the average analysts forecast of $8.6M by -94.67%. Apple's EBITDA was $-62.659M, beating the average prediction of $-1.719M by 3544.89%. The company's net income was $-68.701M, beating the average estimation of $-507K by 13459.21%. Apple's SG&A was $26.58M, missing the average forecast of $6.68B by -99.60%. Lastly, the company's EPS was $-1.16, beating the average prediction of $-0.00625 by 18450.68%. In terms of the last quarterly report (Dec 2022), Verona Pharma's revenue was $458K, missing the average analysts' forecast of $4.08M by -88.76%. The company's EBITDA was $-12.24M, beating the average prediction of $-815K by 1401.48%. Verona Pharma's net income was $-10.451M, missing the average estimation of $372.21K by -2907.85%. The company's SG&A was $8.32M, missing the average forecast of $3.17B by -99.74%. Lastly, the company's EPS was $-0.18, missing the average prediction of $0.00459 by -4018.48%